Surgical repair and replacement for native mitral valve infective endocarditis.
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
medline:
18
3
2024
pubmed:
26
2
2024
entrez:
26
2
2024
Statut:
ppublish
Résumé
The clinical benefits of mitral valve repair over replacement in the setting of mitral infective endocarditis are not clearly established. Data of patients who underwent cardiac surgery for infective endocarditis over a 20-year period (2001-2021) at two cardiac centres were reviewed. Among them, 282 patients underwent native mitral valve surgery and were included in the study. Nearest-neighbour propensity-score matching was performed to account for differences in patients' profile between the repair and replacement subgroups. Mitral valve replacement was performed in 186 patients, while in 96 cases patients underwent mitral valve repair. Propensity match analysis provided 89 well matched pairs. Mean age was 60 ± 15 years; 75% of the patients were male. Mitral valve replacement was more commonly performed in patients with involvement of both mitral leaflets, commissure(s) and mitral annulus. Patients with lesion(s) limited to P2 segment formed the majority of the cases undergoing mitral valve repair. There was no difference in terms of microbiological findings. In-hospital mortality was 7% with no difference between the repair and the replacement cohorts. Survival probabilities at 1, 5 and 10 years were 88%, 72% and 68%, respectively after mitral repair, and 88%, 78% and 63%, respectively after mitral replacement (log-rank P = 0.94). Mitral valve repair was more commonly performed in patients with isolated single leaflet involvement and provided good early and 10-year outcomes. Patients with annular disruption, lesion(s) on both leaflets and commissure(s) were successfully served on early and mid-term course by mitral valve replacement.
Identifiants
pubmed: 38407841
doi: 10.2459/JCM.0000000000001599
pii: 01244665-202404000-00010
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
334-341Informations de copyright
Copyright © 2024 Italian Federation of Cardiology - I.F.C. All rights reserved.
Références
Lee HA, Cheng YT, Wu VC, et al. Nationwide cohort study of mitral valve repair versus replacement for infective endocarditis. J Thorac Cardiovasc Surg 2018; 156:1473–1483.
Toyoda N, Itagaki S, Egorova NN, et al. Real-world outcomes of surgery for native mitral valve endocarditis. J Thorac Cardiovasc Surg 2017; 154:1906–1912.
Moore RA, Witten JC, Lowry AM, et al. Endocarditis Study Group. Isolated mitral valve endocarditis: patient, disease, and surgical factors that influence outcomes. J Thorac Cardiovasc Surg 2024; 167:127–140.
Van Vlasselaer A, Rasmussen M, Nilsson J, Olaison L, Ragnarsson S. Native aortic versus mitral valve infective endocarditis: a nationwide registry study. Open Heart 2019; 6:e000926.
Wang S, Zhou T, Bian J, et al. Clinical outcomes following surgical mitral valve plasty or replacement in patients with infectious endocarditis: a meta-analysis. Front Surg 2023; 9:1048036.
He K, Song J, Luo H, et al. Valve replacement or repair in native mitral valve infective endocarditis – which is better? A meta-analysis and systematic review. J Card Surg 2022; 37:1004–1015.
Harky A, Hof A, Garner M, Froghi S, Bashir M. Mitral valve repair or replacement in native valve endocarditis? Systematic review and meta-analysis. J Card Surg 2018; 33:364–371.
Ng Yin Ling C, Bleetman D, Pal S, et al. Should more patients be offered repair for mitral valve endocarditis? A single-centre 15-year experience. J Cardiothorac Surg 2022; 17:243.
Shih CJ, Chu H, Chao PW, et al. Long-term clinical outcome of major adverse cardiac events in survivors of infective endocarditis: a nationwide population-based study. Circulation 2014; 130:1684–1691.
Makarious Laham M, Easo J, Szczechowicz M, et al. Five-year follow-up of mitral valve repair versus replacement: a propensity score analysis. J Cardiothorac Surg 2023; 18:27.
Squiers JJ, DiMaio JM, Banwait JK, Mack MJ, Ryan WH. Baylor Scott & White Surgery for Endocarditis Working Group. Surgical treatment of infective endocarditis at comprehensive versus primary valve centers. J Thorac Cardiovasc Surg 2021; 166:442–452.
Solari S, De Kerchove L, Tamer S, et al. Active infective mitral valve endocarditis: is a repair-oriented surgery safe and durable? Eur J Cardiothorac Surg 2019; 55:256–262.
Nishimura RA, Otto CM, Bonow RO, et al. ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:2440–2492.
Habib G, Lancellotti P, Antunes MJ, et al. ESC Scientific Document Group. 2015 ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075–3128.
Benedetto U, Head SJ, Angelini GD, Blackstone EH. Statistical primer: propensity score matching and its alternatives. Eur J Cardiothorac Surg 2018; 53:1112–1117.
Brescia AA, Watt TMF, Rosenbloom LM, Williams AM, Bolling SF, Romano MA. Patient and surgeon predictors of mitral and tricuspid valve repair for infective endocarditis. Semin Thorac Cardiovasc Surg 2022; 34:67–77.
Tatum JM, Bowdish ME, Mack WJ, et al. Outcomes after mitral valve repair: a single-center 16-year experience. J Thorac Cardiovasc Surg 2017; 154:822–830. e2.
David TE, David CM, Tsang W, Lafreniere-Roula M, Manlhiot C. Long-term results of mitral valve repair for regurgitation due to leaflet prolapse. J Am Coll Cardiol 2019; 74:1044–1053.
Tomšic A, Versteegh MIM, Ajmone Marsan N, van Brakel TJ, Klautz RJM, Palmen M. Early and late results of surgical treatment for isolated active native mitral valve infective endocarditis. Interact Cardiovasc Thorac Surg 2018; 26:610–616.
Tepsuwan T, Rimsukcharoenchai C, Tantraworasin A, et al. Comparison between mitral valve repair and replacement in active infective endocarditis. Gen Thorac Cardiovasc Surg 2019; 67:1030–1037.
Gammie JS, Sheng S, Griffith BP, et al. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg 2009; 87:1431–1437.
Di Bacco L, D’Alonzo M, Di Mauro M, et al. Mitral valve surgery in acute infective endocarditis: long-term outcomes of mitral valve repair versus replacement. J Cardiovasc Med (Hagerstown) 2024; 25:30–37.
Miura T, Obase K, Ariyoshi T, et al. Impact of lesion localization on durability of mitral valve repair in infective endocarditis. Ann Thorac Surg 2020; 109:1335–1342.
de Kerchove L, Price J, Tamer S, et al. Extending the scope of mitral valve repair in active endocarditis. J Thorac Cardiovasc Surg 2012; 143:S91–S95.
Kehara H, Minakata K, McCarthy J, et al. Early and late results of mitral valve repair with anterior leaflet patch augmentation. Interact Cardiovasc Thorac Surg 2022; 35:ivac144.